ClinicalTrials.gg
CompletedNCT05238701Updated Jan 29, 2024

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

A Phase 1 interventional study of LPM3770164 sustained release tablet and LPM3770164 sustained release tablet simulant in Huntington Disease and Tardive Dyskinesia, sponsored by Luye Pharma Group Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Huntington Disease with a site in China — 3 open to participants now, 4 under way, 1 of them phase 3. Huntington Disease · China.

Enrollment
2nd of 12
104 · median 34
Started
2022
the only one that year
Phase 1
7 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
4 of 12
Luye Pharma Group Ltd.

Among the 12 studies in Huntington Disease with a site in China, this one is the 2nd largest by enrollment, is the only one that started in 2022, is one of 7 in phase 1, and was the 3rd registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

3 of the 12 studies in Huntington Disease with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Huntington Disease with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.

03

Conditions studied

  • Huntington Disease
  • Tardive Dyskinesia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who voluntarily participate and sign the form;
  2. Healthy male/female volunteers aged 18 to 45 years;
  3. Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and (BMI) 18.5 \~ 28.0 kg/m2, inclusive;
  4. Able to comply with the lifestyle restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of allergy to any component of the drug or similar drugs, or allergic constitution;
  2. Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results;
  3. Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;.
  4. Subject has a history of self-mutilation; or at risk of suicide;
  5. Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial;
  6. Subject has abnormal vital signs, laboratory abnormalities, and ECGs;
  7. Subject has used any of over-the-counter products within 14 days or prescription medications within 28 days prior to dosing;
  8. Subject positive for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or syphilis seroreactivity (Trust);
  9. Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results;
  10. Subject has a history of substance abuse or a positive urine drug screen;
  11. Subject who has daily smoking of ≥ 5 cigarettes;
  12. Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration;
  13. Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration;
  14. Subject who has participated in other clinical trials within 3 months before administration;
  15. Subject has used blood products or being blood donor or blood loss;
  16. Pregnant, lactating women, or positive pregnancy test;
  17. Subject who refusal to , or plan to donate sperm or ovums;
  18. Other conditions which would make participation in the study unsuitable.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    LPM3770164

    LPM3770164 sustained-release tablets will be administrated with single dose from 0.5mg to 60mg

    Drug: LPM3770164 sustained release tablet

  • Placebo comparator
    Placebo

    LPM3770164 sustained release tablet simulant will be administrated with single dose

    Drug: LPM3770164 sustained release tablet simulant

Interventions

  • LPM3770164 sustained release tablet will be administrated orally single-dose on day 1

    Also known as: LY03015

  • DrugLPM3770164 sustained release tablet simulant

    LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1

    Also known as: LY03015 simulant

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse effects

    Number of participants with treatment-emergent adverse effects will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment.

    Time frame: from baseline to day 28

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: from baseline to day 15

  2. Time to maximum observed concentration (Tmax)

    Time frame: from baseline to day 15

  3. Area under the concentration-time curve (AUC)

    Time frame: from baseline to day 15

  4. Clearance (CL)

    Time frame: from baseline to day 15

  5. Half-life (t1/2)

    Time frame: from baseline to day 15

  6. Mean Residence Time (MRT)

    Time frame: from baseline to day 15

  7. Haematology

    Time frame: baseline, day 3, day 8, day 15, day 28

  8. Blood Chemistry

    Time frame: baseline, day 3, day 8, day 15, day 28

  9. Urinalysis

    Time frame: baseline, day 15, day 28

  10. Coagulation

    Time frame: baseline, day 15, day 28

  11. Body Temperature

    Time frame: baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28

  12. Respiratory Rate

    Time frame: baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28

  13. Blood Pressure

    Time frame: baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28

  14. Pulse Rate

    Time frame: baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28

  15. Physical Examination

    Time frame: baseline, day 15, day 28

  16. 12 lead electrocardiogram corrected QT interval

    Time frame: baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28

  17. Simpson-Angus Rating Scale (SAS)

    Time frame: baseline, day 3, day 28

  18. Barnes Akathisia Rating Scale (BARS)

    Time frame: baseline, day 3, day 28

  19. Abnormal Involuntary Movement Scale (AIMS)

    Time frame: baseline, day 3, day 28

  20. Stanford Sleepiness Scale (SSS)

    Time frame: baseline, day 3, day 28

07

Study locations

1 site
  • Shanghai Mental Health Center
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2023, 20 months.

Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2022
First posted
Feb 14, 2022
StartActual
Feb 25, 2022
Primary completionActual
Nov 4, 2023
CompletionActual
Nov 4, 2023
Last update
Jan 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238701
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Feb 25, 2022
Primary completion
Nov 4, 2023
Completion
Nov 4, 2023
Last update
Jan 29, 2024

Study contacts

hufang Li, Doctor
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LPM3770164

Start the discussion